Slajd 2

1. A. Kucharczyk AAI Łódź 2023
2. Portacci A et al. Super-responders to biologhic treatment in type 2-high severe asthma: passing fad or a meaningful phenotype? J ALLERGY CLIN IMMUNOL PRACT MAY 2023

Slajd 3

1. Cohn L. J Allergy Clin Immunol 2022; 150: 59-61. 2. Lommatzsch M, et al. Lancet. 2022;399(10335):1664-1668.

Slajd 4

1. Koefoed, Hans Jacob L et al. “Predicting the course of asthma from childhood until early adulthood.” Current opinion in allergy and clinical immunology vol. 22,2 (2022): 115-122

Slajd 5

1. Menzies-Gow, Andrew et al. “An expert consensus framework for asthma remission as a treatment goal.” The Journal of allergy and clinical immunology vol. 145,3 (2020): 757-765. doi:10.1016/j.jaci.2019.12.006

Slajd 5

1. Thomas, Dennis et al. “Asthma remission: what is it and how can it be achieved?.” The European respiratory journal vol. 60,5 2102583. 3 Nov. 2022, doi:10.1183/13993003.02583-2021

Slajd 6

1. Lommatzsch, Marek et al. “Disease-modifying anti-asthmatic drugs.” Lancet (London, England) vol. 399,10335 (2022): 1664-1668. doi:10.1016/S0140-6736(22)00331-2

Slajd 7

1. Lommatzsch, Marek et al. “A2BCD: a concise guide for asthma management.” The Lancet. Respiratory medicine vol. 11,6 (2023): 573-576. doi:10.1016/S2213-2600(22)00490-8

Slajd 8

1. Zhang S i wsp. ERS 2023. Plakat PA1895.

Slajd 9

1. Milger, Katrin, et al. "Response to biologics and clinical remission in the adult German Asthma Net Severe Asthma Registry Cohort." The Journal of Allergy and Clinical Immunology: In Practice 11.9 (2023): 2701-2712.